Table 3.

Adoptive immunotherapy using ex vivo activated Vγ9Vδ2 T cells.

References	No. of Transferred γδ T Cells		Cycle		Route	Exogenous Administration			Clinical Outcome
	Each Cycle	Total	Interval	Cycles		Zol	IL-2: Dose/Schedule
Kobayashi et al., 2007 Cancer Immunol. Immunother. [22]	5 × 106 to 3.57 × 109	0.1–40.8 × 109	Weekly	6–12	iv	No	7 × 105 IU, iv	d1
Bennouna et al., 2008 Cancer Immunol. Immunother. [21]	1 × 109, n = 1	1.45–18.3 × 109	3 weeks	3	iv	No	Cycle 1: no, cycle 2: 2 × 106 IU/m2, sc	d1–d7	SD: 6, PD: 4
	4 × 109, n = 6			16
	8 × 109, n = 3			8
Kobayashi et al., 2011 Cancer Immunol. Immunother. [23]	9.4 × 106–24.0 × 109	1.5×109–46.7 × 109	3 weeks	Average 4.2	iv	4 mg, iv. d1	1.4 × 106 IU, iv	d1–5	SD: 5, PD: 5, CR: 1
	mean: 1.4 × 109	mean: 22.0 × 109
Nicol et al., 2011 Br. J. Cancer [24]	0.04–2.8 × 109	0.1–5.5 × 109		Up to 8	iv	1 mg, iv, 24 h before cell transfer; 1 mg, iv, just before cell transfer	No	No	SD: 2, PD: 4
	0.3–2.2 × 109	1.0–7.2 × 109							SD: 1, PD: 7, NE: 1
	0.3–1.9 × 109	0.9–4.0 × 109							PR: 2, CR: 1
Nakajima et al., 2010 Eur. J. Cardiothorac. Surg. [26]		2.6–31.4 × 109	2 weeks	3–12 (mean 6)	iv	No	No		SD: 3, PD: 5 NE: 2
Abe et al., 2009 Exp. Hematol. [25]	0.07–5.2 × 109	3.0–20.0 × 109	2 weeks	4–8 (mean 7)	iv	No	No		Decreased M-protein levels: 4
Wada et al., 2014 Cancer Med [27]	0.06–6.49 × 109	0.06–25.0 × 109	weekly	1–4 (mean 3)	ip	1 mg, iv at 1st therapy, 1 mg intraperitoneal injection, after 2nd therapy	No		Ascites, disappeared: 1, Reduced: 1, No change: 5